Literature DB >> 26385101

Cost-of-Illness Studies: An Updated Review of Current Methods.

Eberechukwu Onukwugha1, Jacquelyn McRae2, Alex Kravetz3, Stefan Varga4, Rahul Khairnar3, C Daniel Mullins3.   

Abstract

INTRODUCTION: Cost-of-illness (COI) studies provide policy-relevant information for cross-country, longitudinal, and other cost comparisons. Prior studies have called for standardization in COI methods. We investigated trends, identified factors associated with variation in COI estimation methods, and characterized reporting of heterogeneity in COI estimates.
METHODS: The review of COI studies was implemented following (i) a structured search of PubMed, SCOPUS and EMBASE; (ii) a review of abstracts; (iii) a full-text review; and (iv) classification of articles according to six COI estimation methods: Sum_All Medical, Sum_Diagnosis Specific, Matched, Regression, Other_Total and Other_Incremental. Descriptive and multivariable regression analyses were conducted.
RESULTS: Of the 993 studies included in the full-text review, 186 (18.7 %) were Sum_All Medical, 458 (46.1 %) were Sum_Diagnosis Specific, 96 (9.7 %) were Matched, 97 (9.8 %) were Regression, 70 (7.1 %) were Other_Incremental, and 68 (6.9 %) were Other_Total. Compared with the early period, publications in the middle and late period were associated with lower odds of using Sum_All Medical compared with Sum_Diagnosis Specific (adjusted odds ratio [AOR]middle 0.14; 95 % CI 0.07-0.28; AORlate 0.44; 95 % CI 0.29-0.67). Overall, 640 articles (64 %) reported COI estimates across patient groups defined by patient-level factors, while 247 articles (25 %) reported COI estimates across patient groups defined by non-patient-level factors.
CONCLUSION: The disease-specific total costing method (Sum_Diagnosis Specific) was most commonly used and its use increased over the time period covered by this review. The investigation of subgroup heterogeneity in COI estimates represents an area for future research.

Entities:  

Mesh:

Year:  2016        PMID: 26385101     DOI: 10.1007/s40273-015-0325-4

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  21 in total

Review 1.  Economic note: cost of illness studies.

Authors:  S Byford; D J Torgerson; J Raftery
Journal:  BMJ       Date:  2000-05-13

2.  Cost of illness studies: what is good about them?

Authors:  D P Rice
Journal:  Inj Prev       Date:  2000-09       Impact factor: 2.399

Review 3.  Cost of lung cancer: a methodological review.

Authors:  Laurent Molinier; Christophe Combescure; Cristos Chouaïd; Jean-Pierre Daurès; Bruno Housset; Didier Fabre; Alain Grand; Alain Vergnenègre
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  The hot spotters: can we lower medical costs by giving the neediest patients better care?

Authors:  Atul Gawande
Journal:  New Yorker       Date:  2011-01

5.  Cost-of-illness studies: a guide to critical evaluation.

Authors:  Allison Larg; John R Moss
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

6.  "Can we declare victory and move on?" The case against funding burden-of-disease studies.

Authors:  Steven Kymes
Journal:  Pharmacoeconomics       Date:  2014-12       Impact factor: 4.981

7.  Cost-of-illness studies: fact or fiction?

Authors:  D P Rice
Journal:  Lancet       Date:  1994-12-03       Impact factor: 79.321

Review 8.  Methodological considerations in cost of prostate cancer studies: a systematic review.

Authors:  Laurent Molinier; Eric Bauvin; Christophe Combescure; Christel Castelli; Xavier Rebillard; Michel Soulié; Jean-Pierre Daurès; Pascale Grosclaude
Journal:  Value Health       Date:  2008-05-20       Impact factor: 5.725

Review 9.  Cost-of-illness studies in diabetes mellitus.

Authors:  Lorraine Ettaro; Thomas J Songer; Ping Zhang; Michael M Engelgau
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Medical and non-medical direct costs of chronic low back pain in patients consulting primary care physicians in France.

Authors:  Fanny Depont; Elke Hunsche; Abdelilah Abouelfath; Thierno Diatta; Isabelle Addra; Angela Grelaud; Rajaa Lagnaoui; Mathieu Molimard; Nicholas Moore
Journal:  Fundam Clin Pharmacol       Date:  2009-08-12       Impact factor: 2.748

View more
  29 in total

1.  The economic burden of diabetes to French national health insurance: a new cost-of-illness method based on a combined medicalized and incremental approach.

Authors:  Grégoire de Lagasnerie; Anne-Sophie Aguadé; Pierre Denis; Anne Fagot-Campagna; Christelle Gastaldi-Menager
Journal:  Eur J Health Econ       Date:  2017-02-11

2.  Cost-of-illness models for venous thromboembolism: One size does not fit all.

Authors:  Scott D Grosse
Journal:  Thromb Res       Date:  2016-07-30       Impact factor: 3.944

Review 3.  Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review.

Authors:  Jamison Pike; Scott D Grosse
Journal:  Appl Health Econ Health Policy       Date:  2018-12       Impact factor: 2.561

4.  Costs of Invasive Meningococcal Disease: A Global Systematic Review.

Authors:  Bing Wang; Renee Santoreneos; Hossein Afzali; Lynne Giles; Helen Marshall
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

5.  Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?

Authors:  T Joseph Mattingly; C Daniel Mullins; Eberechukwu Onukwugha
Journal:  Pharmacoeconomics       Date:  2016-10       Impact factor: 4.981

6.  How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts.

Authors:  Simon Wieser; Marco Riguzzi; Mark Pletscher; Carola A Huber; Harry Telser; Matthias Schwenkglenks
Journal:  Eur J Health Econ       Date:  2018-02-22

7.  Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.

Authors:  Kristina R Dahlstrom; Shuangshuang Fu; Wenyaw Chan; Zeena Shelal; Lois M Ramondetta; David R Lairson
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

8.  Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations.

Authors:  Scott D Grosse; Kurt V Krueger; Jamison Pike
Journal:  J Med Econ       Date:  2018-11-15       Impact factor: 2.448

Review 9.  Economic assessments of the burden of congenital cytomegalovirus infection and the cost-effectiveness of prevention strategies.

Authors:  Scott D Grosse; Sheila C Dollard; Ismael R Ortega-Sanchez
Journal:  Semin Perinatol       Date:  2021-01-23       Impact factor: 3.300

10.  Spending on Young Children With Autism Spectrum Disorder in Employer-Sponsored Plans, 2011-2017.

Authors:  Scott D Grosse; Xu Ji; Phyllis Nichols; Samuel H Zuvekas; Catherine E Rice; Marshalyn Yeargin-Allsopp
Journal:  Psychiatr Serv       Date:  2020-10-20       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.